IpIBA seminar series 2022/2023“Exploiting nanobodies targeting ABCC3 for glioblastoma immunoguided applications.”
Glioblastoma is the most aggressive primary brain tumor in adults. Efficiency of current diagnostic methods and therapeutic strategies of glioblastoma is narrowed by the presence of the molecular-restrictive blood-brain barrier (BBB), and the belated translation of relevant biomarkers into the clinical practice. New efforts emerge towards a personalized medicine, based on molecularly matched formulations against specific tumor biomarkers of this heterogeneous tumor. Due to their molecular features, nanobodies emerge as novel promising immunotargeted tools for glioblastoma.
CIBA, main meeting room, and online via zoom
Importante las plazas son limitadas: 100 presencial y 100 modalidad on line. Si participa de forma presencial no hace falta realizar inscripción on line.